Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
about
Differences in management of older women influence breast cancer survival: results from a population-based database in SwedenChemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women.Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.Long-term health outcomes of a decision aid: data from a randomized trial of adjuvant! In women with localized breast cancer.Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?Spectrum of very early breast cancer in a setting without organised screening.Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.Evaluating the Completeness of the SEER-Medicare Linked Database for Oral and Pharyngeal CancerContemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma.Review of diagnostic imaging modalities for the surveillance of melanoma patientsBreast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Treatment of breast cancer in medically underserved women: a review.Breast cancer treatment of older women in integrated health care settings.Can differences in breast cancer utilities explain disparities in breast cancer care?Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural GeorgiaThe influence of aging on the early detection, diagnosis, and treatment of breast cancer.Occupational type affects the receipt of breast cancer adjuvant chemotherapy in China.Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901.Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollmentLymphocyte depletion and repopulation after chemotherapy for primary breast cancer.Selecting high priority quality measures for breast cancer quality improvementDisparities in use of gynecologic oncologists for women with ovarian cancer in the United StatesCommunity-based assessment of adjuvant hormone therapy in women with breast cancer, 1991-1997.Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older womenExternal validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohortClinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer.Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly womenAssessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelinesAdjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy.Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer.Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.Ethnic disparities in breast cancer management among Asian Americans and Pacific Islanders.The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
P2860
Q25257242-DD2E3A73-93A2-4F32-84E0-58AC2F4EFD87Q30403036-447C7DBF-CC59-459E-9E45-3313CDFF97F4Q33258573-E255AFE1-7574-430D-A3DC-335B7E210729Q33385774-DF567952-08B2-4E6E-9CB8-B690808338A5Q33415916-E04042A5-632D-4D03-AE05-87A4630B9449Q33553921-9A2FC80D-2491-4D0A-A97A-C7730A8F8AE8Q33555289-CCE22EAE-C5BC-4109-9180-63DC5F43170CQ33990818-6D004D08-D26B-4DE0-BEFF-35393716D3AEQ34179020-0883B8ED-329B-4DB7-AB5F-4869AE1A90B5Q34498776-6ADAC7DC-C191-426B-B26C-E931467EED8AQ34974893-1DD4D0F9-0E23-46B4-94FA-EDE97AAB3AD5Q35184338-62CFA76F-3EE1-4CFA-B591-3C077C093FBEQ35490056-8C273879-5B8E-4362-B1D0-68AFAA2A8680Q35626368-28CEC6F9-AB7D-44BF-BE27-58147345C505Q35879504-369E738E-D364-43BC-8D44-5CDCB65B8025Q35901636-5A56C041-3114-4EA1-B21F-141754B42064Q35984047-DC48C51F-5C31-475F-9AC4-42CEAC6287E8Q35989721-B18BE98C-7D9C-4F6A-B980-3AF9C65A7B0DQ36086033-DD288640-CC60-4116-B763-067E3F853610Q36145423-74944198-7E16-49CE-BF76-E76C173FB548Q36344983-B3CAB4E2-6314-451A-B132-225D6B59CF0EQ36494003-D2E6C9F8-269C-4A6B-BF7C-E8899EE85469Q36503756-27B864F0-563B-40EE-B10D-132A0E780E2AQ36511958-BB3130A0-A481-4150-97FD-CE9431735F2BQ36925424-3CAFA2BA-2772-4F21-A5EC-11C52A3159C0Q36935104-717C5186-E53C-49E8-A162-3CC9A2E87A6BQ36936078-67D2F453-AAFD-449C-85D9-F1823B2E57BAQ36936083-D26280E4-6F95-46B3-A6E0-8085E993A45AQ36949179-F07C7E05-8980-438B-9AE0-B5296F0B1E8BQ37038642-B57A3A76-E58A-44DF-A022-2E2CF95A007CQ37117143-BA5BA34C-6D86-4BB5-8000-7858CEBAF2EEQ37276942-A5BB0BEB-3B48-42CB-970B-A2EFB88D034BQ37408456-21843AD8-409F-4372-B5CF-42F0DAD9BAABQ37492422-ABBEA686-922E-46BF-8F4E-ABA0C95DA684Q37884483-3B9B25EB-133C-460E-9777-F97F84166024Q38710235-AB41F4D5-CF1E-48C5-B551-863EBC646C47Q39717577-EF42CAB9-6FE6-4475-A0DD-582418B29542Q44217768-EAE1E503-F6ED-487B-BAC1-0A3C85E8981EQ45301624-D09DFA1F-1D07-4A4A-93DE-8E1A4A3115ADQ46271859-DE296075-400D-4210-9273-2A597E4B9D61
P2860
Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Discrepancy between consensus ...... y in women with breast cancer.
@en
type
label
Discrepancy between consensus ...... y in women with breast cancer.
@en
prefLabel
Discrepancy between consensus ...... y in women with breast cancer.
@en
P2093
P2860
P1476
Discrepancy between consensus ...... y in women with breast cancer.
@en
P2093
Charles R Key
Cynthia Osborne
James S Goodwin
Jonathan D Mahnken
Xianglin L Du
P2860
P356
10.7326/0003-4819-138-2-200301210-00009
P407
P577
2003-01-01T00:00:00Z